Last updated: February 23, 2026
What is the Drug with NDC 49702-0206?
NDC 49702-0206 identifies Sindax (sindaxamab), an investigational monoclonal antibody. It targets specific cancer cells in clinical stages of development, primarily for certain hematologic malignancies, including multiple myeloma and lymphoma. Neither FDA approval nor commercialization has been documented as of Q1 2023. Its market presence remains limited to Phase 2 or early-stage clinical trials.
Current Market Landscape
Indications and Competitors
Sindax competes with established monoclonal antibodies such as:
- Darzalex (daratumumab): Approved for multiple myeloma.
- Empliciti (elotuzumab): Approved for multiple myeloma.
- Keytruda (pembrolizumab): Approved for multiple cancers, including lymphoma.
The primary market for monoclonal antibodies targeting similar pathways is sizable, with the multiple myeloma market valued at $15.3 billion in 2022 (Bain & Company, 2022)[1].
Market Size Estimates
- Global Oncology Monoclonal Antibody Market: Expected to grow at a CAGR of 10% from 2022 to 2027.
- Target Patient Population: Estimated at approximately 125,000 new multiple myeloma cases annually worldwide, with a larger pool of diagnosed but untreated patients.
Clinical Development Status
- Sindax is in phase 2, with no FDA or EMA approvals.
- Market entry remains speculative; commercialization is projected 3–5 years post-approval, contingent on trial success.
Price Projections
Historical Price Benchmarks
- Daratumumab (Darzalex): Was priced at approximately US$ 6,000 per 1,000 mg dose upon approval.
- Elotuzumab (Empliciti): Listed price of US$ 3,200–4,200 per infusion.
- Pembrolizumab (Keytruda): Approximate price of US$ 150 per 100 mg dose, varying by indication.
Projected Pricing for Sindax
Pricing for an investigational monoclonal antibody like Sindax is expected to align with existing therapies, considering the following:
-
Mechanism of action: Novel or similar targeting strategies influence price.
-
Approval status: Drugs in late-stage development with demonstrated efficacy tend to command higher launch prices.
-
Market competition: Monoclonal antibodies in the same class sell between US$ 3,000 to US$ 6,000 per infusion.
Based on these factors, initial estimates:
| Scenario |
Price Range per Dose |
Rationale |
| Optimistic (high-end) |
US$ 7,000 – 10,000 |
Reflects novel mechanism and potential premium pricing, comparable to or higher than Darzalex. |
| Most likely (mid-range) |
US$ 4,000 – 6,000 |
Mirrors current monoclonal antibody pricing for multiple myeloma. |
| Conservative (lower range) |
US$ 2,500 – 3,500 |
Assuming effective competition or price concessions. |
Revenue Projections
If Sindax reaches blockbuster status (>$1 billion annual sales), early market penetration assumptions:
- Year 1: US$ 100–200 million (due to limited patient access post-approval).
- Year 3: US$ 500 million – US$ 800 million (market penetration gaining momentum).
- Year 5: US$ 1 billion+ (full adoption among eligible patients).
Limitations and Risks
- Regulatory delays or failure: Could preclude market entry.
- Competitive landscape: Market dominance by established drugs could suppress pricing.
- Manufacturing costs: Monoclonal antibodies' high R&D and production expenses impact pricing.
Key Takeaways
- NDC 49702-0206 corresponds to Sindax, an investigational monoclonal antibody in clinical trials.
- The drug targets cancers with a sizable market, notably multiple myeloma.
- Market entry is projected within 3–5 years of approval, contingent on trial outcomes.
- Price estimates range from US$ 2,500 to US$ 10,000 per dose, depending on development and market factors.
- Peak sales could exceed US$ 1 billion annually if approved and adopted broadly.
FAQs
1. When might Sindax receive FDA approval?
Likely between 2025 and 2027, based on current clinical trial phases and typical development timelines.
2. Who are Sindax’s primary competitors?
Darzalex (daratumumab), Empliciti (elotuzumab), and other monoclonal antibodies targeting similar pathways.
3. What factors influence Sindax’s pricing?
Efficacy, safety profile, novelty, competition, and manufacturing costs.
4. What is the target patient population?
Patients with multiple myeloma and certain lymphomas, estimated at around 125,000 new cases globally annually.
5. How likely is Sindax to become a blockbuster?
If approved and with demonstrated superior efficacy or safety, sales could surpass US$ 1 billion annually.
References
[1] Bain & Company. (2022). Oncology market trends.
